Ishino, Takamasa
Kawashima, Shusuke
Tanji, Etsuko
Ueno, Toshihide
Ueda, Youki
Ogasawara, Sadahisa
Sato, Kazuhito
Mano, Hiroyuki http://orcid.org/0000-0003-4645-0181
Ishihara, Soichiro
Kato, Naoya
Kawazu, Masahito
Togashi, Yosuke http://orcid.org/0000-0001-9910-0164
Article History
Received: 10 October 2022
Revised: 11 January 2023
Accepted: 13 January 2023
First Online: 2 February 2023
Competing interests
: SO received honoraria from Bayer, Eisai, Eli Lilly and Chugai Pharmaceutical, and research grants from Bayer, Eisai, Eli Lilly, Chugai Pharmaceutical and AstraZeneca. NK received honoraria from MSD, Bristol-Myers Squibb Company, Chugai Pharmaceutical, and AstraZeneca, and a research grant from Chugai Pharmaceutical. YT has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, and MSD and research grants from Ono Pharmaceutical, Bristol-Myers Squibb, Daiichi-Sankyo, KOTAI Biotechnologies, and KORTUC outside of this study. All other authors declare that they have no competing financial interests.
: The clinical protocol for this study was approved by the appropriate institutional review boards and ethics committees at the National Cancer Center (#2015-202) and the University of Tokyo (G10063 and G10094). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained prior to participation. Mouse experiments were approved by the Animal Committee for Animal Experimentation of the Chiba Cancer Center (21–3) and Okayama University (629). All experiments met the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals.